Mast cell proteases

Therapeutic Targets in Airway Inflammation

Volumn , Issue , 2003, Pages 349-372

  Fang, Kenneth C ^a   Caughey, George H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248218881     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (141)

1. Schwartz LB. Neutral proteases of mast cells. In: Hanson LA, Shakib F, eds. Monographs in Allergy. Vol. 27. Basel: Karger, 1990:165.
2. Caughey GH, ed. Mast Cell Proteases in Immunology and Biology. New York: Marceldekker, 1995:354.
3. Caughey GH. Of mites and men: Trypsin-like proteases in the lungs. Am J Respir CellMol Biol 1997; 16:621-628.
4. Lagunoff D, Benditt EP. Proteolytic enzymes of mast cells. Ann NY Acad Sci 1963;103:185-198.
5. Glenner GG, Cohen LA. Histochemical demonstration of a species-specific trypsinlike enzyme in mast cells. Nature 1960; 185:846-847.
6. Fraki JE, Hopsu-Havu VK. Human skin proteases: Separation and characterization oftwo alkaline proteases, one splitting trypsin and the other chymotrypsin substrates.Arch Dermatol Res 1975; 253:261-276.
7. Fraki JE. Human skin proteases: Effect of separated proteases on vascular permeabilityand leukocyte emigration in skin. Acta Dermatovener 1977; 57:393-398.
8. Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells.Purification and characterization. J Biol Chem 1981; 256:11939-11943.
9. Tanaka T, McRae BJ, Cho K, et al. Mammalian tissue trypsin-like enzymes. Comparative reactivities of human skin tryptase, human lung tryptase, and bovine trypsin withpeptide 4-nitroanilide and thioester substrates. J Biol Chem 1983; 258:13552-13557.
10. Smith TJ, Hougland MW, Johnson DA. Human lung tryptase. Purification and characterization. J Biol Chem 1984; 259:11046-11051.
11. Vanderslice P, Craik CS, Nadel JA, Caughey GH. Molecular cloning of dog mast celltryptase and a related protease: Structural evidence of a unique mode of serine proteaseactivation. Biochemistry 1989; 28:4148-4155.
12. Miller JS, Westin EH, Schwartz LB. Cloning and characterization of complementaryDNA for human tryptase. J Clin Invest 1989; 84:1188-1195.
13. Vanderslice P, Ballinger SM, Tam EK, Goldstein SM, Craik CS, Caughey GH. Humanmast cell tryptase: Multiple cDNAs and genes reveal a multigene serine protease family.Proc Natl Acad Sci USA 1990; 87:3811-3815.
14. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of humanmast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA1986; 83:4464-4468.
15. Xia H-Z, Kepley CL, Sakai K, Chelliah J, Irani A-M. A, Schwartz LB. Quantitationof tryptase, chymase, FceRIa, and FceRIy mRNAs in human mast cells and basophilsby competitive reverse transcription-polymerase chain reaction. J Immunol 1995; 154:5472-5480.
16. Li L, Li Y, Reddel SW, et al. Identification of basophilic cells that express mast cellgranule proteases in the peripheral blood of asthma, allergy, and drug-reactive patients.J Immunol 1998; 161:5079-86.
17. Pallaoro M, Fejzo MS, Shayesteh L, Blount JL, Caughey GH. Characterization ofgenes encoding known and novel human mast cell tryptases on chromosome 16p 13.3.J Biol Chem 1999; 274:3355-3362.
18. Sakai K, Ren S, Schwartz LB. A novel heparin-dependent processing pathway forhuman tryptase: Autocatalysis followed by activation with dipeptidyl peptidase I. J ClinInvest 1996; 97:988-995.
19. Huang C, Li L, Krilis SA, et al. Human tryptases a and p/II are functionally distinctdue, in part, to a single amino acid difference in one of the surface loops that formsthe substrate-binding cleft. J Biol Chem 1999; 274:19670-19676.
20. Schwartz LB, Sakai K, Bradford TR, et al. The alpha form of human tryptase is thepredominant type present in blood at baseline in normal subjects and is elevated inthose with systemic mastocytosis. J Clin Invest 1995; 96:2702-2710.
21. Kanthawatana S, Carias K, Arnaout R, Hu J, Irani AM, Schwartz LB. The potentialclinical utility of serum a-protryptase levels. J Allergy Clin Immunol 1999; 103:1092-1099.
22. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serumconcentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenopterastings. Lancet 2001; 357:361-362.
23. Guida M, Riedy M, Lee D, Hall J. Characterization of two highly polymorphic humantryptase loci and comparison with a newly discovered monkey tryptase ortholog. Pharmacogenetics 2000; 10:389-396.
24. Caughey GH, Raymond WW, Blount JL, et al. Characterization of human y-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families.J Immunol 2000; 164:6566-6575.
25. Schwartz LB, Lewis RA, Seldin D, Austen KF. Acid hydrolases and tryptase fromsecretory granules of dispersed human lung mast cells. J Immunol 1981; 126:1290-1294.
26. Harris JL, Niles A, Burdick K, et al. Definition of the extended substrate specificitydeterminants for p-tryptases I and II. J Biol Chem 2001; 276:34941-34947.
27. Pereira PJB, Bergner A, Macedo-Ribeiro S, et al. Human p-tryptase is a ring-liketetramer with active sites facing a central pore. Nature 1998; 392:306-311.
28. Caughey GH, Leidig F, Viro NF, Nadel JA. Substance P and vasoactive intestinalpeptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988;244:133-137.
29. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase.Am J Respir Cell Mol Biol 1990; 3:27-32.
30. Imamura T, Dubin A, Moore W, Tanaka R, Travis J. Induction of vascular permeabilityenhancement by human tryptase: Dependence on activation of prekallikrein and directrelease of bradykinin from kininogens. Lab Invest 1996; 74:861-870.
31. Kozik A, Moore RB, Potempa J, Imamura T, Rapala-Kozik M, Travis J. A novelmechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreinson native and oxidized kininogens. J Biol Chem 1998; 273:33224-33229.
32. Schwartz LB, Bradford TR, Littman BH, Wintroub BU. The fibrinolytic activity ofpurified tryptase from human lung mast cells. J Immunol 1985; 135:2762-2767.
33. Gruber BL, Marchese MJ, Suzuki K, et al. Synovial procollagenase activation byhuman mast cell tryptase. Dependence upon matrix metalloproteinase 3 activation. JClin Invest 1989; 84:1657-1662.
34. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-typeplasminogen activator (pro-urokinase). J Biol Chem 1994; 269:9416-9419.
35. Corvera CU, Dery O, McConalogue K, et al. Mast cell tryptase regulates rat colonicmyocytes through proteinase-activated receptor 2. J Clin Invest 1997; 100:1383-1393.
36. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase withthrombin receptors and PAR-2. J Biol Chem 1997; 272:4043-4049.
37. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6:151-158.
38. Schmidlin F, Amadesi S, Vidil R, et al. Expression and function of proteinase-activatedreceptor 2 in human bronchial smooth muscle. Am J Respir Crit Care Med 2001; 164:1276-1281.
39. Compton SJ, Renaux B, Wijesuriya SJ, Hollenberg MD. Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) by human mast cell tryptase. Br JPharmacol 2001; 134:705-718.
40. Sekizawa K, Caughey GH, Lazarus SC, Gold WM, Nadel JA. Mast cell tryptase causesairway smooth muscle hyperresponsiveness in dogs. J Clin Invest 1989; 83:175-179.
41. Clark JM, Abraham WM, Fishman CE, et al. Tryptase inhibitors block allergen-inducedairway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med1995; 152:2076-2083.
42. Johnson PRA, Ammit AJ, Carlin SM, Armour CL, Caughey GH, Black JL. Mast celltryptase potentiates histamine-induced contraction in human sensitized bronchus. EurResp J 1997; 10:38-43.
43. Berger P, Compton SJ, Molimard M, et al. Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchi. Clin Exp Allergy 1999; 29:804-812.
44. Molinari JF, Scuri M, Moore WR, Clark J, Tanaka R, Abraham WM. Inhaled tryptasecauses bronchoconstriction in sheep via histamine release. Am J Respir Crit Care Med1996; 154:649-653.
45. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for culturedfibroblasts. J Clin Invest 1991; 88:493-499.
46. Brown JK, Tyler CL, Jones CA, Ruoss SJ, Hartmann T, Caughey GH. Tryptase, thedominant secretory granular protein in humans mast cells, is a potent mitogen forcultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:227-236.
47. Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells—stimulationof IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996;156:275-283.
48. Gruber BL, Kew RR, Jelaska A, et al. Human mast cells activate fibroblasts: Tryptaseis a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis andfibroblast chemotaxis. J Immunol 1997; 158:2310-2317.
49. Cairns JA, Walls AF. Mast cell tryptase stimulates synthesis of type I collagen inhuman lung fibroblasts. J Clin Invest 1997; 99:1313-1321.
50. Thomas VA, Wheeless CJ, Stack MS, Johnson DA. Human mast cell tryptase fibrino-genolysis: Kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 1998; 37:2291-2298.
51. Compton SJ, Cairns JA, Holgate ST, Walls AF. The role of mast cell tryptase inregulating endothelial cell proliferation, cytokine release, and adhesion moleculeexpression: Tryptase induces expression of mRNA for IL-1 pand IL-8 and stimulatesthe selective release of IL-8 from human umbilical vein endothelial cells. J Immunol1998; 161:1939-1946.
52. He SH, Walls AF. Human mast cell tryptase: A stimulus of microvascular leakage andmast cell activation. Eur J Pharmacol 1997; 328:89-97.
53. Huang C, De Sanctis GT, O’Brien PJ, et al. Evaluation of the substrate specificity ofhuman mast cell tryptase p 1 and demonstration of its importance in bacterial infectionsof the lung. J Biol Chem 2001; 276:26276-26284.
54. Blair RJ, Meng H, Marchese MJ, et al. Human mast cells stimulate vascular tubeformation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99:2691-2700.
55. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells upregulateangiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13:1382-1397.
56. Caughey GH, Raymond WW, Bacci E, Lombardy RJ, Tidwell RR. Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mastcell tryptases. J Pharmacol Exp Therap 1993; 264:676-682.
57. Sturzebecher J, Prasa D, Sommerhoff CP. Inhibition of human mast cell tryptase bybenzamidine derivatives. Biol Chem Hoppe Seyler 1992; 373:1025-1030.
58. Kam CM, Hernandez MA, Patil GS, et al. Mammalian tissue trypsin-like enzymes:substrate specificity and inhibitory potency of substituted isocoumarin mechanism-based inhibitors, benzamidine derivatives, and arginine fluoroalkyl ketone transition-state inhibitors. Arch Biochem Biophys 1995; 316:808-814.
59. Katz BA, Clark JM, Finer-Moore JS, et al. Design of potent selective zinc-mediatedserine protease inhibitors. Nature 1998; 391:608-612.
60. Janc JW, Clark JM, Warne RL, Elrod KC, Katz BA, Moore WR. A novel approachto serine protease inhibition: Kinetic characterization of inhibitors whose potencies andselectivities are dramatically enhanced by zinc(II). Biochemistry 2000; 39:4792-4800.
61. Krishna MT, Chauhan AJ, Little L, et al. Effect of inhaled APC 366 on allergen-induced bronchoconstriction and airway hyperresponsiveness to histamine in atopicsubjects. Am J Respir Crit Care Med. 1998; 157:A456.
62. Rice KD, Wang VR, Gangloff AR, et al. Dibasic inhibitors of human mast cell tryptase.Part 2: Structure-activity relationships and requirements for potent activity. BioorgMed Chem Lett 2000; 10:2361-2366.
63. Burgess LE, Newhouse BJ, Ibrahim P, et al. Potent selective nonpeptidic inhibitors ofhuman lung tryptase. Proc Natl Acad Sci USA 1999; 96:8348-8352.
64. Schaschke N, Matschiner G, Zettl F, et al. Bivalent inhibition of human p-tryptase.Chem Biol 2001; 8:313-327.
65. Ono S, Kuwahara S, Takeuchi M, Sakashita H, Naito Y, Kondo T. Syntheses andevaluation of amidinobenzofuran derivatives as tryptase inhibitors. Bioorg Med ChemLett 1999; 9:3285-3290.
66. Wright CD, Havill AM, Middleton SC, et al. Inhibition of allergen-induced pulmonaryresponses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesul-fonylamino)-methyl] -phenoxy]-pentane (AMG-126737). Biochem Pharmacol 1999;58:1989-1996.
67. Combrink KD, HB GI, Meanwell NA, et al. 1,2-Benzisothiazol-3-one 1,1-dioxideinhibitors of human mast cell tryptase. J Med Chem 1998; 41:4854-4860.
68. Sommerhoff CP, Sollner C, Mentele R, Piechottka GP, Auerswald EA, Fritz H. A Kazal-type inhibitor of human mast cell tryptase: Isolation from the medicinal leechHirudo medicinalis, characterization, and sequence analysis. Biol Chem Hoppe-Seyler1994; 375:685-694.
69. Stubbs MT, Morenweiser R, Sturzebecher J, et al. The three-dimensional structure ofrecombinant leech-derived tryptase inhibitor in complex with trypsin. Implications forthe structure of human mast cell tryptase and its inhibition. J Biol Chem 1997; 272:19931-19937.
70. Elrod KC, Moore WR, Abraham WM, Tanaka RD. Lactoferrin, a potent tryptaseinhibitor, abolishes late-phase airway responses in allergic sheep. Am J Respir CritCare Med 1997; 156:375-381.
71. Cregar L, Elrod KC, Putnam D, Moore WR. Neutrophil myeloperoxidase is a potentand selective inhibitor of mast cell tryptase. Arch Biochem Biophys 1999; 366:125-130.
72. Wong GW, Tang Y, Feyfant E, et al. Identification of a new member of the tryptasefamily of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension. J Biol Chem 1999; 274:30784-30793.
73. Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C, Travis J. Molecular cloningof human cathepsin G: Structural similarity to mast cell and cytotoxic T lymphocyteproteinases. Biochemistry 1987; 26:2289-2293.
74. Caughey GH, Zerweck EH, Vanderslice P. Structure, chromosomal assignment, anddeduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem1991; 266:12956-12963.
75. Hof P, Mayr I, Huber R, et al. The 1.8 A crystal structure of human cathepsin G incomplex with Suc-Val-Pro-PheP-(OPh)2: A Janus-faced proteinase with two oppositespecificities. EMBO J 1996; 15:5481-5491.
76. Pereira PJB, Wang ZM, Rubin H, et al. The 2.2 A crystal structure of human chymasein complex with succinyl-Ala-Ala-Pro-Phe-chloromethylketone: Structural explanationfor its dipeptidyl carboxypeptidase specificity. J Mol Biol 1999; 286:163-173.
77. Caughey GH, Schaumberg TH, Zerweck EH, et al. The human mast cell chymasegene (CMA1): Mapping to the cathepsin G/granzyme gene cluster and lineage-restrictedexpression. Genomics 1993; 15:614-620.
78. Schechter NM, Irani AM, Sprows JL, Abernethy J, Wintroub B, Schwartz LB. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. JImmunol 1990; 145:2652-2661.
79. Matin R, Tam EK, Nadel JA, Caughey GH. Distribution of chymase-containing mastcells in human bronchi. J Histochem Cytochem 1992; 40:781-786.
80. Suzuki H, Caughey GH, Gao X-P, Rubinstein I. Mast cell chymase-like protease(s)modulates Escherichia coli lipopolysaccharide-induced vasomotor dysfunction in skeletal muscle in vivo. J Pharmacol Exp Therap 1998; 284:1156-1164.
81. Shiota N, Okunishi H, Takai S, et al. Tranilast suppresses vascular chymase expressionand neointima formation in balloon-injured dog carotid artery. Circulation 1999; 99:1084-1090.
82. Kielty CM, Lees M, Shuttleworth CA, Woolley D. Catabolism of intact type VI collagen microfibrils: Susceptibility to degradation by serine proteinases. Biochem BiophysRes Commun 1993; 191:1230-1236.
83. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymaseand leukocyte elastase release latent transforming growth factor-p 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270:4689-4696.
84. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-lengthendothelins by chymase from human mast cells. J Immunol 1997; 159:1987-1992.
85. Sommerhoff CP, Caughey GH, Finkbeiner WE, Lazarus SC, Basbaum CB, Nadel JA.Mast cell chymase. A potent secretagogue for airway gland serous cells. J Immunol1989; 142:2450-2456.
86. Sommerhoff CP, Ruoss SJ, Caughey GH. Mast cell proteoglycans modulate the secretagogue, proteoglycanase, and amidolytic activities of dog mast cell chymase. J Immunol1992; 148:2859-2866.
87. Aoyama Y, Uenaka M, Kii M, et al. Design, synthesis and pharmacological evaluationof 3-benzylazetidine-2-one-based human chymase inhibitors. Bioorg Med Chem 2001;9:3065-3075.
88. Akahoshi F, Ashimori A, Sakashita H, et al. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase. J Med Chem 2001; 44:1297-1304.
89. Groutas WC, Schechter NM, He S, Yu H, Huang P, Tu J. Human chymase inhibitorsbased on the 1,2,5-thiadiazolidin-3-one-1, 1-dioxide scaffold. Bioorg Med Chem Lett1999; 9:2199-2204.
90. Sillaber C, Baghestanian M, Bevec D, et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999; 162:1032-1041.
91. Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissueremodeling. FASEB J 1991; 5:2145-2154.
92. Tozzi CA, Thakker-Varia S, Yu SY, et al. Mast cell collagenase correlates with regression of pulmonary vascular remodeling in the rat. Am J Respir Cell Mol Biol 1998;18:497-510.
93. Tanaka A, Arai K, Kitamura Y, Matsuda H. Matrix metalloproteinase-9 production, a newly identified function of mast cell progenitors, is downregulated by c-kit receptoractivation. Blood 1999; 94:2390-2395.
94. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mastcells produce matrix metalloproteinase 9. Eur J Immunol 1999; 29:2645-2649.
95. Brownell E, Fiorentino L, Jolly G, et al. Immunolocalization of stromelysin-relatedprotein in murine mast cell granules. Int Arch Allergy Immunol 1995; 107:333-335.
96. Fang KC, Raymond WW, Lazarus SC, Caughey GH. Dog mastocytoma cells secretea 92-kD gelatinase activated extracellularly by mast cell chymase. J Clin Invest 1996;97:1589-1596.
97. 92 bonds of the catalyticdomain. J Biol Chem 1997; 272:25628-25635.
98. Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, Caughey GH. Mast cellexpression of gelatinases A and B is regulated by kit ligand and TGF-p. J Immunol1999; 162:5528-5535.
99. Frank BT, Rossall JC, Caughey GH, Fang KC. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by a-chymase. J Immunol 2001;166:2783-2792.
100. Di Girolamo N, Wakefield D. In vitro and in vivo expression of interstitial collagenase/MMP-1 by human mast cells. Dev Immunol 2000; 7:131-142.
101. 84 bond by mast cell chymase.J Biol Chem 1994; 269:18134-18140.
102. Suzuki K, Lees M, Newlands GF, Nagase H, Woolley DE. Activation of precursorsfor matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by ratmast-cell proteinases I and II. Biochem J 1995; 305:301-306.
103. Lees M, Taylor DJ, Woolley DE. Mast cell proteinases activate precursor forms ofcollagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem 1994;223:171-177.
104. Van Wart HE, Birkedal-Hansen H. The cysteine switch: A principle of regulation ofmetalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87:5578-5582.
105. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activatesthe precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267:3581-3584.
106. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9)by gelatinase A (MMP-2). Cancer Res 1995; 55:2548-2555.
107. Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem1985; 260:2493-2500.
108. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mastcells release metalloproteinase-9 on contact with activated t cells: Juxtacrine regulationby TNF-alpha. J Immunol 2001; 167:4008-4016.
109. Tanaka A, Yamane Y, MatsudaH. Mast cell MMP-9 production enhanced by bacteriallipopolysaccharide. J Vet Med Sci 2001; 63:811-813.
110. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: Identification of adistinct gelatinase-containing granule subset by combined immunocytochemistry andsubcellular fractionation. Blood 1993; 82:3183-3191.
111. Hoshino M, Nakamura Y, Sim J, Shimojo J, Isogai S. Bronchial subepithelial fibrosisand expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998; 102:783-788.
112. Mautino G, Henriquet C, Jaffuel D, Bousquet J, Capony F. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am JRespir Crit Care Med 1999; 160:324-330.
113. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma andchronic bronchitis. Am J Respir Crit Care Med 1998; 158:1945-1950.
114. Lemjabbar H, Gosset P, Lamblin C, et al. Contribution of 92 kDa gelatinase/type IVcollagenase in bronchial inflammation during status asthmaticus. Am J Respir CritCare Med 1999; 159:1298-1307.
115. Vliagoftis H, Schwingshackl A, Milne CD, et al. Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy ClinImmunol 2000; 106:537-545.
116. Foda HD, George S, Rollo E, et al. Regulation of gelatinases in human airway smoothmuscle cells: Mechanism of progelatinase A activation. Am J Physiol 1999; 277:L174-182.
117. Ohno I, Ohtani H, Nitta Y, et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997; 16:212-219.
118. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Dexamethasone selectivelymodulates basal and lipoplysaccharide-induced metalloproteinase and tissue inhibitorof metalloproteinase production by human alveolar macrophages. J Immunol 1991;146:2724-2729.
119. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrixmetalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages ofasthmatics. Am J Respir Cell Mol Biol 1997; 17:583-591.
120. Bosse M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrixmetalloproteinase-9; tissue inhibitor of metalloproteinase-1 ratio correlates with steroidresponsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999; 159:596-602.
121. Hoshino M, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy ClinImmunol 1999; 104:356-363.
122. Swartz MA, Tschumperlin DJ, Kamm RD, Drazen JM. Mechanical stress is communicated between different cell types to elicit matrix remodeling. Proc Natl Acad Sci USA2001; 98:6180-6185.
123. Kumagai K, Ohno I, Okada S, et al. Inhibition of matrix metalloproteinases preventsallergen-induced airway inflammation in a murine model of asthma. J Immunol 1999;162:4212-4219.
124. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. AmJ Respir Crit Care Med 1997; 156:229-233.
125. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmaticairways: Relation to inhaled steroid dose. Thorax 1999; 54:289-295.
126. Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growthplate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93:411-422.
127. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancertherapy. J Natl Cancer Inst 2001; 93:178-193.
128. Riley DJ, Thakker-Varia S, Wilson FJ, Polani GJ, Tozzi CA. Role of proteolysis andapoptosis in regression of pulmonary vascular remodeling. Physiol Res 2000; 49:577-585.
129. Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P. Elevatedlevels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle.Am J Respir Cell Mol Biol 1999; 20:199-208.
130. Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degradingmetalloproteinases by mast cell proteases in atherosclerotic plaques. ArteriosclerThromb Vasc Biol 1998; 18:1707-1715.
131. Dahlen B, Shute J, Howarth P. Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma. Thorax 1999; 54:590-596.
132. Lee YC, Song CH, Lee HB, et al. A murine model of toluene diisocyanate-inducedasthma can be treated with matrix metalloproteinase inhibitor. J Allergy Clin Immunol2001; 108:1021-1026.
133. Corbel M, Caulet-Maugendre S, Germain N, Molet S, Lagente V, Boichot E. Inhibitionof bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinaseinhibitor batimastat. J Pathol 2001; 193:538-545.
134. Foda HD, Rollo EE, Drews M, et al. Ventilator-Induced Lung Injury Upregulates andActivates Gelatinases and EMMPRIN. Attenuation by the synthetic matrix metalloproteinase inhibitor, prinomastat (AG3340). Am J Respir Cell Mol Biol 2001; 25:717-724.
135. Carney DE, Lutz CJ, Picone AL, et al. Matrix metalloproteinase inhibitor preventsacute lung injury after cardiopulmonary bypass. Circulation 1999; 100:400-406.
136. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell a-and p-chymases. Biochim Biophys Acta 2000; 1480:245-257.
137. Wolters PJ, Laig-Webster M, Caughey GH. Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways. AmJ Respir Cell Mol Biol 2000; 22:183-190.
138. McGuire MJ, Lipsky PE, Thiele DL. Generation of active myeloid and lymphoidgranule serine proteases requires processing by the granule thiol protease dipeptidylpeptidase I. J Biol Chem 1993; 268:2458-2467.
139. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl peptidase Iis essential for activation of mast cell chymases, but not tryptases, in mice. J BiolChem 2001; 276:18551-18556.
140. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosedhuman skin mast cell protease-proteoglycan complexes: Tryptase resides in a complexdistinct from chymase and carboxypeptidase. J Immunol 1992; 148:2475-2482.
141. Goldstein SM. Mast cell carboxypeptidase: Structure and regulation of gene expression.In: Caughey GH. ed. Mast Cell Proteases in Immunology and Biology. New York:Marcel Dekker, 1995:109-126.